Boye KS - Search Results

1

Treatment approach and HbA1c control among US adults with type 2 diabetes: NHANES 1999-2004.

Dodd AH, Colby MS, Boye KS, Fahlman C, Kim S, Briefel RR. Dodd AH, et al. Among authors: boye ks. Curr Med Res Opin. 2009 Jul;25(7):1605-13. doi: 10.1185/03007990902973300. Curr Med Res Opin. 2009. PMID: 19469695

2

Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.

Ray JA, Boye KS, Yurgin N, Valentine WJ, Roze S, McKendrick J, Tucker DM, Foos V, Palmer AJ. Ray JA, et al. Among authors: boye ks. Curr Med Res Opin. 2007 Mar;23(3):609-22. doi: 10.1185/030079907X178685. Curr Med Res Opin. 2007. PMID: 17355742 Clinical Trial.

3

Obesity and incremental hospital charges among patients with and without diabetes in the United States.

Kim S, Boye KS. Kim S, et al. Among authors: boye ks. Value Health. 2009 Jul-Aug;12(5):723-9. doi: 10.1111/j.1524-4733.2008.00501.x. Value Health. 2009. PMID: 19508656 Free article.

4

Excessive hospitalizations and its associated economic burden among people with diabetes in the United States.

Kim S, Boye KS. Kim S, et al. Among authors: boye ks. Value Health. 2009 Mar-Apr;12(2):267-72. doi: 10.1111/j.1524-4733.2008.00443.x. Value Health. 2009. PMID: 20667061 Free article.

5

A model of mild hypoglycemia.

Samuel S, Goswami D, Shum K, Boye KS, Rengarajan B, Curtis B, Curtis SE. Samuel S, et al. Among authors: boye ks. Curr Med Res Opin. 2015 Apr;31(4):633-41. doi: 10.1185/03007995.2015.1020363. Epub 2015 Mar 17. Curr Med Res Opin. 2015. PMID: 25690489

6

The relationship between HbA1c reduction and healthcare costs among patients with type 2 diabetes: evidence from a U.S. claims database.

Lage MJ, Boye KS. Lage MJ, et al. Among authors: boye ks. Curr Med Res Opin. 2020 Sep;36(9):1441-1447. doi: 10.1080/03007995.2020.1787971. Epub 2020 Jul 17. Curr Med Res Opin. 2020. PMID: 32643451

7

Obese versus non-obese patients with type 2 diabetes: patient-reported outcomes and utility of weight change.

Matza LS, Yurgin N, Boye KS, Malley K, Shorr JM. Matza LS, et al. Among authors: boye ks. Curr Med Res Opin. 2007 Sep;23(9):2051-62. doi: 10.1185/030079907X219454. Curr Med Res Opin. 2007. PMID: 17651535

8

Comparing clinical and economic characteristics between commercially-insured patients with diabetic neuropathy and demographically-matched diabetic controls.

Zhao Y, Ye W, Le TK, Boye KS, Holcombe JH, Swindle R. Zhao Y, et al. Among authors: boye ks. Curr Med Res Opin. 2009 Mar;25(3):585-97. doi: 10.1185/03007990802706289. Curr Med Res Opin. 2009. PMID: 19232033

9

A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo.

Scott DA, Boye KS, Timlin L, Clark JF, Best JH. Scott DA, et al. Among authors: boye ks. Diabetes Obes Metab. 2013 Mar;15(3):213-23. doi: 10.1111/dom.12007. Epub 2012 Oct 3. Diabetes Obes Metab. 2013. PMID: 22958381 Review.

10

Physician perceptions of GLP-1 receptor agonists in the UK.

Matza LS, Curtis SE, Jordan JB, Adetunji O, Martin SA, Boye KS. Matza LS, et al. Among authors: boye ks. Curr Med Res Opin. 2016 May;32(5):857-64. doi: 10.1185/03007995.2016.1147025. Epub 2016 Feb 12. Curr Med Res Opin. 2016. PMID: 26807507

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

139 results

Search Page